ANNUAL UPDATES
FROM ASH 2018:

Practice Changing Abstracts

Chicago, Illinois |  February 15, 2019

MICHAEL BISHOP, MD
COURSE DIRECTOR

Director of the Hematopoietic Cellular Therapy Program
University of Chicago Medicine

 
natasha-taylor-188224-1.jpg

Course Description

Patients in medically underserved communities have limited access to subspecialty care. Community-based oncologists are well positioned to provide initial care for these patients, but often do not have the knowledge and confidence to manage difficult cases. According to the 2015 Community Health Needs Assessment, between 2006 and 2008, the City of Chicago experienced an annual average adjusted cancer mortality rate of 194.2 deaths per 100,000 individuals. Cancer mortality has decreased over the past decade in Cook County; the same trend is apparent both statewide and nationwide. Although both trends are decreasing, Cook County cancer related mortality is greater than the national average deaths per 100,000 individuals. Also, city of Chicago cancer mortality rates are higher than regional, state, and national cancer death rates. University experts in hematological cancers agree that we need to join our regional cancer community to lower our county and state mortality rate. Also, many local health professionals do not have the time or resources available to attend the annual updates from ASH 2018 conference where the latest scientific and clinical research in blood cancers is discussed, so they need a venue in which they can learn about these important updates.

Target Audience

This activity has been designed for physicians and other healthcare professionals interested in the treatment of hematologic cancers.

Learning Objectives

 
  • Discuss how comprehension of biology of leukemias has influenced treatment approaches;

  • Describe next generation improvements in CAR T-cell therapies that can improve patient outcomes;

  • Identify methods for integrating therapeutic advances into practice to improve current myeloma patient care;

  • List current best practice in first and second line therapies for lymphoid malignancies;

  • Name new technologies for the treatment of hemophilia;

  • Analyze how new scientific insights are informing diagnosis and treatment of myelodysplastic/myeloproliferative neoplasms.

Location

 

University of Chicago
The Gleacher Center
450 Cityfront Plaza Dr,
Chicago, IL 60611